RT Journal Article
SR Electronic
T1 Brain development mutations in the β-tubulin TUBB result in defective ciliogenesis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.05.23.23290232
DO 10.1101/2023.05.23.23290232
A1 Mollica, Antonio
A1 Omer, Safia
A1 Evagelou, Sonia L.
A1 Naumenko, Serhiy
A1 Li, Lu Yi
A1 Teeling, Aideen
A1 Lindsay, Kyle
A1 Erwood, Steven
A1 Vernon, Robert M.
A1 Forman-Kay, Julie D.
A1 Shroff, Manohar
A1 Harrison, Rene E.
A1 Cohn, Ronald D.
A1 Ivakine, Evgueni A.
YR 2023
UL http://medrxiv.org/content/early/2023/05/28/2023.05.23.23290232.abstract
AB Tubulinopathies and neurodevelopmental ciliopathies are two groups of genetic disorders characterized by abnormal brain development resulting in structural brain malformations. Tubulinopathies are caused by dominant missense mutations in genes encoding for tubulins, the building blocks of microtubules. Neurodevelopmental ciliopathies are mostly recessive disorders caused by defects in the function of the primary cilium, a sensory organelle that modulates signaling pathways important for brain development. Though more than 40 genes have been associated with neurodevelopmental ciliopathies, many patients still do not have an identified genetic etiology. Herein, we present a novel de novo heterozygous missense variant in Tubulin Beta Class I (TUBB) identified through whole-genome sequencing analysis in a patient with both ciliopathy and tubulinopathy brain features. While microtubules are fundamental to primary cilia formation and function, no association between mutations in tubulin genes and neurodevelopmental ciliopathies has been found to date. Using patient-derived cells and gene-edited isogenic cell lines, we show that the identified variant impairs the early stages of cilia formation by altering microtubule dynamics and structure. Furthermore, we demonstrate that the disease mechanism is not haploinsufficiency and that other patient mutations in TUBB affect cilia formation in vitro, putting forward defective ciliogenesis as a contributing pathogenic factor in a subset of tubulinopathy patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the Nicol Family Foundation, the SickKids Foundation, and by a grant from the Rare Disease Foundation and the BC Childrens Hospital FoundationAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Research Ethics Board (REB) of The Hospital for Sick Children, Toronto, Ontario, Canada gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors